VERICEL CORPORATION Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount
VERICEL CORPORATION (VCEL) reported Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount of $2.86 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxExemptIncome · last filed 2026-02-26
- VERICEL CORPORATION effective income tax rate reconciliation, tax exempt income, amount for fiscal 2025 was $2.86M, a 56.38% decline from fiscal 2024.
- VERICEL CORPORATION effective income tax rate reconciliation, tax exempt income, amount for fiscal 2024 was $6.55M, a 1017.24% increase from fiscal 2023.
- VERICEL CORPORATION effective income tax rate reconciliation, tax exempt income, amount for fiscal 2023 was $586.00K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount 12 month |
|---|---|
| 2025-12-31 | $2.86M 10-K · filed 2026-02-26 |
| 2024-12-31 | $6.55M 10-K · filed 2026-02-26 |
| 2023-12-31 | $586.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |